Country Access Report
Hungary maintains a restrictive legal regime for classic psychedelics: most tryptamines, phenethylamines and plant/fungal preparations (psilocybin, DMT, 5‑MeO‑DMT, MDMA, mescaline, ibogaine, ayahuasca, 2C‑X) are controlled and have no routine medical availability outside approved clinical research. Esketamine (Spravato) is authorised in the EU and listed in Hungarian product databases and can be delivered through licensed medical services; reimbursement pathways exist but are limited and administratively gated. Ketamine is legally available as an anaesthetic and is used off‑label in psychiatric practice (including private clinics), but routine public reimbursement for psychiatric ketamine therapy is not established and is handled case‑by‑case (named‑patient or special financing).
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under Hungarian criminal law, with explicit statutory thresholds and no authorised medical use outside of approved clinical research. The Hungarian penal provisions list psilocybin among controlled substances and define possession/trafficking thresholds; there is no national medical reimbursement pathway for psilocybin therapy at present. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorised medical use outside of approved clinical research. There is no publicly funded MDMA‑assisted therapy program in Hungary and possession/traffic is criminalised under the Hungarian legal framework. [1]
Compound Access
Esketamine (marketed as Spravato) is authorised at the European level for treatment‑resistant depression and is available in EU member states under the EMA marketing authorisation for Spravato. [1].
In Hungary Spravato appears in national product databases and commercial prescribing resources (product listing entries indicate prescription status and show TB/financing metadata), and local pharmacy/product listings show a patient price point and reimbursement/támogatás metadata; this indicates Spravato is placed on the Hungarian market and can be supplied via prescription in clinical settings. [2].
Reimbursement/access nuances: Hungarian public reimbursement is managed by the National Health Insurance Fund (NEAK) and special/named‑patient financing processes exist for high‑cost or exceptional therapies. Recent Hungarian regulatory updates (2025) changed named‑patient reimbursement decision pathways (introduction of a public benefit foundation handling certain named‑patient requests alongside NEAK), which may affect individual funding decisions for off‑list or special therapies; therefore access and coverage for Spravato may be provided either through standard reimbursement if listed by NEAK or via special/named‑patient processes depending on the indication, contractual status and clinical documentation. [3], [4].
Practically, Spravato must be administered under supervision in a clinical setting per the EMA SmPC; clinics offering it typically operate under specialist psychiatric services and billing will depend on whether the product is covered by NEAK (regular reimbursement) or provided via special financing/named‑patient arrangements. Where publicly reimbursed, prior authorisation and clinical criteria (treatment‑resistant major depressive disorder after at least two failed antidepressant trials, plus co‑administration with an oral antidepressant and supervised administration) are required. [1].
Compound Access
Ketamine is a legally authorised medicine in Hungary (widely used as an anaesthetic and analgesic) and is explicitly referenced in criminal law thresholds (i.e., controlled‑substance scheduling), but it is also used off‑label in psychiatry for depressive disorders in some clinical settings. The Hungarian penal provisions list ketamine among controlled substances for the purposes of defining possession thresholds, confirming its controlled status even as a medicine. [1].
Clinical/practical context: Ketamine infusion or intranasal ketamine is provided in hospital and private clinic settings for anaesthesia and, increasingly, as off‑label psychiatric therapy for treatment‑resistant depression. Off‑label psychiatric ketamine programmes are typically delivered by specialist clinics and billed privately; routine, standardized public reimbursement for ketamine when used for psychiatric indications is not broadly established and is handled on a case‑by‑case basis (e.g., hospital budget lines, special financing, or private payment). NEAK special financing and named‑patient pathways can in theory be used for non‑standard therapies but require institutional approvals and documentation. [2], [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Civilian possession, distribution, or preparation of DMT‑containing preparations (including ayahuasca/Yopo preparations where DMT is present) is criminalised, and there is no routine reimbursement pathway. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No routine medical availability or public reimbursement; any clinical research would require regulatory approvals and institutional oversight. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no organised, reimbursed ibogaine treatment program in Hungary. [1].
Compound Access
Ayahuasca preparations containing DMT are unlawful in Hungary because their active alkaloids (DMT) are controlled substances; as such, ayahuasca has no authorised medical pathway outside of approved clinical research. Importation, distribution or ceremonial use involving DMT would fall under controlled‑substance prohibitions. [1].
Compound Access
Currently classified as a strictly controlled substance under national scheduling; mescaline and mescaline‑containing cacti preparations are not authorised for medical use in Hungary outside clinical trials. Possession and distribution are criminalised under Hungarian drug law. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorised medical use outside of approved clinical research. Designer phenethylamines in the 2C family are explicitly policed in Hungary’s evolving drug enforcement framework; no reimbursement or medical access exists outside regulated trials. [1], [2].
Last updated 2 Mar 2026. Source links come from the medical access guide.